Aether Industries Q4 FY26: Growth accelerates as Site 3++ ramps and Site 5 nears production

Aether Industries closed FY26 with a sharp improvement in scale and profitability, supported by a richer business mix and steady customer momentum. On a consolidated basis, revenue from operations rose to INR 1,160 crore in FY26, up 38% from INR 841 crore in FY25. EBITDA increased faster than revenue, reaching INR 355 crore with a 31% margin versus 28% last year. Profit after tax rose to INR 220 crore, translating into a 19% PAT margin.

The company attributed the year’s performance primarily to its Contract Exclusive Manufacturing and CRAMS models. In FY26, Contract Exclusive Manufacturing accounted for 46.3% of revenue and CRAMS for 9.2%, taking the combined share above 55%. Large Scale Manufacturing contributed 43.2%, while other income streams were small.

Q4 FY26 was a mixed quarter. Operating revenue grew 27% year on year to INR 305 crore, but fell sequentially from Q3 FY26 due to one-off impacts and shipment timing. EBITDA in Q4 was INR 81 crore and PAT was INR 54 crore. Management explained that Q3 included a one-time FLOP claim income, while Q4 absorbed a provision for inventory loss from a fire at an external warehouse and certain year-end provisions.

The mix continues to shift toward contract-led models

Aether’s business model split offers a clear view of how the company intends to evolve. Management has consistently highlighted that CRAMS can feed into CEM over time as customer relationships deepen and products move from development to exclusive manufacturing.

In FY26, the company reported the following revenue mix by business model: 46.3% from CEM, 43.2% from LSM, 9.2% from CRAMS, and 1.3% from others. The presentation also showed that quarterly contribution from CEM has been rising sharply over the last three comparable fourth quarters.

From an end-market perspective, FY26 revenue was diversified across multiple sectors. Pharma remained the largest at 34.2%, followed by oil and gas at 21.1% and material science at 17.7%. Agro contributed 12.2%. Smaller segments included multiple at 6.2%, high performance photography at 4.7%, coatings at 2.8%, and sustainability and renewables at 1.0%.

This is a notable shift compared with FY25 when pharma represented 45.6% of revenue. Oil and gas increased significantly as a share, while agro reduced as a share. Management also highlighted that material science is expected to grow meaningfully with faster ramp-up of Site 3++.

Site 3++ and Site 5 are the operational catalysts

The most important near-term execution lever is manufacturing capacity. The company stated that Site 3++ commenced production in late February and is being ramped up. The investor presentation indicated that strategic supply from Site 3++ is expected to ramp up in Q1 FY27.

Site 5 is the larger catalyst. Phase 1, consisting of two production blocks, has begun water and solvent trials and commercial production is expected to start in June 2026, which aligns with Q1 FY27. In the earnings call, management said validation batches are done and orders are already in hand for three new large scale manufacturing products, two in pharma and one in agrochemical, planned to be commissioned by late May or early June.

Management also provided color on the physical scale of Site 5. Four blocks have already been constructed. Two are ready to run and trials are ongoing. Work has started on additional blocks with groundwork underway before the monsoon. In total, Site 5 is planned for 16 production blocks, and the adjacent Site 5 plus land could support about four more blocks, taking the combined land bank to about 45 to 46 acres.

In addition to manufacturing, Aether continued to highlight customer readiness. The company stated it completed 50-plus customer and certification audits and onboarded 19 new customers in FY26. It also noted that multiple customers have completed pre-audits for Site 5.

R and D spend stays high as capability expands

Aether’s strategy remains R and D centric. The company spent INR 86.2 crore on R and D in FY26, representing 7.3% of revenues. Management also referred to the interim R and D expansion as completed, with two new labs, 18 fume hoods and a 400 MHz NMR machine installed. Commercialization of this expanded interim capability is expected to begin from Q2 onwards of the current fiscal year.

The longer-term R and D build-out is a new R and D building and wing expected to be commissioned in Q2 FY28. Management described it as having 15 new labs including five engineering labs and about 140 fume hoods. The stated objective is to support increased CRAMS inquiries and build capacity with visibility of future project load.

Management also highlighted organisational investments. It said the team structure is being reaffirmed to meet requirements, with an average employee age of 30 years. It also announced expansion of the global technology and business development team with the addition of a senior hire based in Germany, intended to deepen capabilities in material sciences and application testing.

Cash flows, working capital, and leverage remain key watch points

While FY26 profitability improved strongly, cash flow dynamics show the cost of rapid expansion. Consolidated net cash from operating activities improved to INR 142.4 crore in FY26 from INR 100.0 crore in FY25. However, investing cash outflow was INR 619.4 crore, leading to a year-end cash balance of INR 5.7 crore versus INR 238.5 crore last year.

Working capital remains elevated, though it improved. Management stated the working capital cycle reduced to 179 days at March 31, 2026 from 194 days a year earlier. The CFO explained inventory days increased due to raw material purchases and work-in-progress linked to new molecules at Site 3++ and procurement for Site 5. Management expects working capital days to decline as deliveries from Site 3++ ramp and Site 5 starts commercial operations. In the Q and A, the CFO also agreed with an expectation of working capital days trending towards 160.

Leverage increased and is expected to rise further due to capex. Consolidated current borrowings rose to INR 442 crore in FY26 from INR 183 crore in FY25. Management stated that debt will increase gradually as project progress requires funding. It guided that an additional INR 200 to 250 crore of debt could be added by end of FY27.

On capex, the CFO indicated that across Site 5 and R and D expansion, total planned capex could be about INR 1,500 to 1,600 crore over the next four years. The company also stated that Site 5 is targeting asset turns of 1.5 to 1.75.

Management commentary on pricing and near-term environment

Aether’s Q4 commentary included an unusual external driver: conflict-related disruption in global oil and petrochemical markets. Management said global disruption caused strong pricing in the large scale manufacturing vertical in Q4, with prices up over 20% year on year and 18% quarter on quarter. It also noted prices remained strong in April and May, and suggested this environment could remain for the next two to three quarters.

At the same time, management clarified that for CEM, cost escalation is structured as open cost, limiting negative impact from raw material price volatility. For LSM, it acknowledged there can be a margin delta in periods of price movements.

The company also addressed safety concerns after two fire-related events. Management described the March 2026 external warehouse fire as a non-event in terms of operational impact, noting there were no injuries and that the fire originated from a neighboring premises. It stated that safety systems worked well and additional measures are being implemented.

Separately, the CFO provided an update on the November 2023 Site 2 fire, stating that the final fixed asset claim has been submitted and is being assessed, with expected settlement by end of Q1 FY27.

Takeaways from Q4 FY26

Aether’s FY26 performance reflects a company benefiting from a mix shift towards higher-value, contract-led business models, while maintaining a high R and D intensity. The next phase depends on clean execution. Site 3++ ramp-up and Site 5 Phase 1 commissioning are positioned as the main revenue drivers for FY27. Management also indicated margin stability expectations, with EBITDA margin guided around 29% to 30% and PAT margin around 19% to 20%.

The key investor focus areas remain working capital discipline, funding strategy amid large capex, and consistency of execution as new capacity comes online. If commissioning timelines hold and working capital improves as deliveries scale, the company’s stated direction of increasing CEM and CRAMS contribution appears aligned with its operational build-out and R and D investments.